Multidrug resistance ABC transporter ATP-binding/permease protein BmrA
Target name: Multidrug resistance ABC transporter ATP-binding/permease protein BmrA
Gene: bmrA
Uniprot Accession: O06967
Origin: Bacillus subtilis (strain 168)
Class: Multidrug resistance ABC transporter
Sequence: Full-length, wildtype sequence, with a N-terminus 6xHis-tag.
Affinity Tag: His-tag (N-terminal)
Catalogue number: PP3
Theor. MW: 64.5 kDa
Shipment temperature: Dry Ice
Storage conditions: Store at -80°C
Expression system: Escherichia coli (BL21C43)
Purity: >90%
Purification: Immobilized Metal Affinity Chromatography
Activity: Confirmed by ATPase activity assay
Concentration: Up to 5mg/ml
Sample buffer: 50mM Tris-Cl pH 8.0, 100 mM NaCl, 0.01% DDM, 10%glycerol
Available quantity: From 10µg up to mg scale
Multidrug resistance ABC transporter ATP-binding/permease protein BmrA: We utilize a unique & custom method to give us the edge
CALIXAR’s Multidrug resistance ABC transporter ATP-binding/permease protein BmrA expedites reliable fragment-based drug design (FBDD), structure-based medication discovery (SBDD) and antibody development against this specific target.
Unlike CALIXAR’s BmrA membrane targets, other alternative approaches result in a BmrA membrane protein that becomes mutated and truncated.
As with all transporters, Multidrug resistance ABC transporter ATP-binding/permease protein BmrA is unpredictable targets, difficult to produce natively without particular technology. Traditionally, BmrA membrane proteins were often developed in a solution that naturally could not be pure, nor native (truncated, mutated), and consequently are moderately unstable.
Thanks to CALIXAR’s expertise, we are able to deliver BmrA membrane targets that maintain the structure and function of the target. Our Multidrug resistance ABC transporter ATP-binding/permease protein BmrA is pure, native, unaltered and stable.
CALIXAR has the capacity to provide high quality, native, wild-type, unaltered, unmutated and untruncated targets for antibody development and pharmaceutical discovery projects. We are unparalleled in the market and at the vanguard of Membrane Protein technology.
CALIXAR’s Multidrug resistance ABC transporter ATP-binding/permease protein BmrA is the first native full-length and functional target on the market. Other existing BmrA membrane targets are either mutated or truncated. Our BmrA membrane protein is produced in a prokaryotic system.
CALIXAR’s BmrA membrane target is high-quality membrane proteins utilized for (bio)drug discovery and is adapted for use in pharmaceutical companies, biotechnology companies, as well as for academic teams that are involved in the life science domains.
- Antibodies (including nanobodies, scaffold proteins, aptamers)
- Small molecules
- 3D Structures (classical X-ray or XFEL, Cryo-EM, NMR)
- Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
- Antibody discovery (Immunization and display technologies)
- Clinical stage (drug validation on reliable native BmrA)
